Industry
Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Loading...
Open
2.49
Mkt cap
289M
Volume
114K
High
2.49
P/E Ratio
-4.11
52-wk high
3.46
Low
2.30
Div yield
N/A
52-wk low
2.19
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 10:06 am
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 10:06 am
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 10:09 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 3:58 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 6:16 pm
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 4:03 pm
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 11:06 am
Portfolio Pulse from Benzinga Insights
March 29, 2024 | 12:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.